FDA Scrutiny Raises Predictability Concerns for Pharmaceutical Industry

The U.S. Food and Drug Administration (FDA) has recently denied or discouraged applications for multiple experimental drugs, leading to concerns among investors and pharmaceutical companies regarding regulatory predictability. This follows a string of recent rejections for treatments targeting hard-to-treat diseases.

The U.S. Food and Drug Administration (FDA) has recently denied or discouraged applications for multiple experimental drugs, leading to concerns among investors and pharmaceutical companies regarding regulatory predictability.

Over the past year, at least eight drugs have faced such decisions.

Recent Rejections Highlight Trend

Examples include UniQure's gene therapy for Huntington's disease, Regenxbio's gene therapy for Hunter syndrome, and Disc Medicine's drug for a blood condition. The FDA initially declined to review Moderna's flu shot application before reversing its stance.

Evidence Concerns Versus Prior Guidance

The agency's rejections were often attributed to issues with the evidence provided by companies, such as a lack of placebo-controlled studies or reliance on biomarkers instead of directly measuring drug efficacy. Companies involved have stated that these decisions contradict prior FDA guidance, causing apprehension among investors about the future of other treatments in development.

Analysts Point to Inconsistency, Market Impact

Analysts have noted a perceived lack of consistency from the FDA.

RBC Capital Markets analyst Luca Issi commented that investors and stakeholders seek consistency, which appears to be lacking.

This uncertainty is impacting companies like Dyne Therapeutics, Taysha Gene Therapies, Wave Life Sciences, and Lexeo Therapeutics, all of which have seen their stock prices decline this year. Dyne Therapeutics stated it maintains frequent and collaborative dialogue with the FDA and remains confident in its strategy.

Key Decision Awaits Denali Therapeutics

One upcoming decision closely monitored by Stifel analyst Paul Matteis is Denali Therapeutics' drug candidate for Hunter syndrome. Its application for accelerated approval is based on a non-randomized trial and data showing a decrease in a disease-associated biomarker. The FDA delayed its review, with a decision expected by April 5.

FDA Responds: "No Regulatory Uncertainty"

An FDA spokesperson stated that there is "no regulatory uncertainty," asserting that the agency makes decisions based on evidence and conducts rigorous, independent reviews.

The agency makes decisions based on evidence and conducts rigorous, independent reviews.

A senior FDA official clarified that the FDA has not changed its position on accepting biomarkers for accelerated approval or non-randomized data for full approval under specific conditions. These conditions include cases where a treatment shows immediate and dramatic improvement in severely ill patients.

Randomized data is requested when a condition is heterogeneous, the will to believe is strong, the therapy is invasive or potentially harmful, the effect size is difficult to detect, and the possibility of self-deception is high.